trending Market Intelligence /marketintelligence/en/news-insights/trending/wyzojglcdatme7uw0ubmyg2 content esgSubNav
In This List

Nuformix adds nonexecutive director to board

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Nuformix adds nonexecutive director to board

Nuformix PLC appointed Christopher Blackwell as a nonexecutive director of the company.

Blackwell served as the CEO of Vectura Group PLC from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion, Nuformix said in a statement.

Cambridge, U.K.-based Nuformix uses cocrystal technology to improve small molecule drugs.

Blackwell will assist the company as it develops its NXP002 programme for the treatment of fibrosis.